Impact Of Major Molecular Response On Overall Survival and Its Time Of Achievement On Complete Molecular Response Incidence In Chronic Myeloid Leukemia Patients Treated By Tyrosine Kinase Inhibitors In First Chronic Phase
Mauricette Michallet(Université Claude Bernard Lyon 1), Xavier Thomas(Hôpital Lyon Sud), Madeleine Etienne(Hôpital Lyon Sud), Fiorenza Barraco(Hôpital Lyon Sud), Isabelle Tigaud(Inserm), Oriane Le Borgne(Hôpital Lyon Sud), Mohamad Sobh(Ottawa Hospital), Sandrine Hayette(Hôpital Claude Huriez), Sophie Ducastelle(Hôpital Lyon Sud), Hélène Labussière(Hôpital Lyon Sud), Lila Gilis(Hospices Civils de Lyon)
Cited by 1
Related Papers
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
|The Lancet|2012|1k
Should Adolescents With Acute Lymphoblastic Leukemia Be Treated as Old Children or Young Adults? Comparison of the French FRALLE-93 and LALA-94 Trials
|Journal of Clinical Oncology|2003|606
Pediatric-Inspired Therapy in Adults With Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia: The GRAALL-2003 Study
|Journal of Clinical Oncology|2009|562
Outcome of Treatment in Adults With Acute Lymphoblastic Leukemia: Analysis of the LALA-94 Trial
|Journal of Clinical Oncology|2004|547